Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT07331727
Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation (EAT-DARE-AF)
Efficacy of Dapagliflozin on Catheter Ablation Outcomes in Persistent Atrial Fibrillation Patients With Increased Epicardial Adipose Tissue
Sponsor: Shanghai Chest Hospital
Conditions
Atrial Fibrillation (AF)
Updated 1 time since 2026 Last updated: Dec 29, 2025 Started: Jan 1, 2026 Primary completion: Sep 30, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This NA trial investigates Atrial Fibrillation (AF) and is currently actively recruiting participants. Shanghai Chest Hospital leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Chest Hospital
Data source: Shanghai Chest Hospital
For direct contact, visit the study record on ClinicalTrials.gov .